Literature DB >> 2119657

The effects of sodium and calcium in clinical hypertension: mediating role of vitamin D metabolism.

L M Resnick1.   

Abstract

On the basis of this work, we believe it is reasonable to suggest that calcium regulating hormones in general, and 1,25 dihydroxyvitamin D in particular, contribute to the pathophysiology of human essential hypertension, especially salt sensitive forms. As such, levels of plasma renin activity, circulating ionized calcium, and serum 1,25 D levels both contribute to and serve as predictors of dietary salt-sensitivity and the potential benefit of increased oral calcium intake. Mechanistically, the different metabolic set points of these factors, determined on a genetic and/or environmental basis, serve to determine the heterogeneous blood pressure responses to similar dietary and mineral intakes. In this scheme, these monovalent and divalent ion regulating hormones transduce environmental mineral signals at the cellular level, thus determining their ultimate blood pressure effects. The cellular mechanism by which these altered metabolic hormonal set points serve to shift levels of intracellular cytosolic free calcium and other critical determinants of blood pressure, are the focus of current research.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2119657

Source DB:  PubMed          Journal:  Adv Second Messenger Phosphoprotein Res        ISSN: 1040-7952


  3 in total

1.  Serum calcium levels in patients with essential hypertension and their first degree relatives.

Authors:  K Sudhakar; M Sujatha; S Ramesh Babu; P Padmavathi; P P Reddy
Journal:  Indian J Clin Biochem       Date:  2004-01

2.  Serum calcium level in hypertension.

Authors:  Mohammed Abdul Hannan Hazari; Mehnaaz Sameera Arifuddin; Syed Muzzakar; Vontela Devender Reddy
Journal:  N Am J Med Sci       Date:  2012-11

3.  A review of nutritional factors in hypertension management.

Authors:  Ha Nguyen; Olaide A Odelola; Janani Rangaswami; Aman Amanullah
Journal:  Int J Hypertens       Date:  2013-04-10       Impact factor: 2.420

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.